Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night

Abstract

Get full access to this article

View all access options for this article.

References

Tramacere

Del Giovane

Salanti

et al . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. Cochrane Database Syst Rev 2015; 9: CD011381.

Montalbán

Gold

Thompson

et al . ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24: 96–120.

Rae-Grant

Day

Marrie

et al . Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018 (in press).

Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Introduction. In: Graham

Mancher

Wolman

et al . (eds) Clinical practice guidelines we can trust (pp. 15–28). Washington, DC: National Academies Press, 2011.

Graham

Harrison

MB.

Evaluation and adaptation of clinical practice guidelines. Evid Based Nurs 2005; 8: 68–72.

Brouwers

Kho

Browman

et al . AGREE II: Advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839–E842.

Woolf

Grol

Hutchinson

et al . Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527–530.

Montalban

Hauser

Kappos

et al . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–220.

Confavreux

Hutchinson

Hours

et al . Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285–291.

10.

Portaccio

Ghezzi

Hakiki

Postpartum relapses increase the risk of disability progression in multiple sclerosis: The role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014; 85: 845–850.

11.

Giannini

Portaccio

Ghezzi

et al . Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: A prospective observational multicentric study. BMC Neurol 2012; 12: 124.

12.

Alroughani

Alowayesh

Ahmed

et al . Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology 2018; 90: e840–e846.

13.

Meinl

Havla

Hohlfeld

et al . Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. Mult Scler. Epub ahead of print 1 September 2017. DOI: 10.1177/1352458517731913.

14.

Portaccio

Moiola

Martinelli

et al . Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology 2018; 90: e832–e839.

15.

Portaccio

Annovazzi

Ghezzi

et al . Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology 2018; 90: e823–e831.

16.

Macklin

Enrolling pregnant women in biomedical research. Lancet 2010; 375: 632–633.

17.

Kappos

Weinshenker

Pozzilli

et al . Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology 2004; 63: 1779–1787.

18.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452.

19.

Hintzen

Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents – Commentary. Mult Scler 2016; 22: 1653–1654.

20.

Marrie

Miller

Sormani

et al . The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology 2016; 86: 1437–1445.